⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CING News
Cingulate Inc. Common Stock
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
globenewswire.com
CING
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
globenewswire.com
CING
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
globenewswire.com
CING